Belgium· BE-AMP-SAM662602-00
Ryzneuta 20 mg
A efbemalenograstim alfa product containing efbemalenograstim alfa, registered in Belgium by Fisiopharma. The same ATC class is registered in 9 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Efbemalenograstim alfa is registered in 9 of 19 countries.
Countries holding a registration under ATC L03AA18 (efbemalenograstim alfa), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 6 of them publish a price we can compare per daily dose
Efbemalenograstim alfa · ATC L03AA18
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Efbemalenograstim Alfa
- Manufacturer
- Fisiopharma
- Country
- Belgium (BE)
- ATC code
- L03AA18
- ATC class
- Efbemalenograstim alfa
- Defined daily dose
- 20 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Efbemalenograstim alfa in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRYZNEUTAFISIOPHARMA S.R.L., NUCLEO INDUSTRIALE, PALOMONTE
- IcelandRyzneutaEvive Biotechnology Ireland Limited
- PolandRyzneutaFisiopharma S.r.l.
- SwedenRyzneuta 20 mg Injektionsvätska, lösning i förfylld sprutaFisiopharma S.r.l.
- FinlandRyzneutaFisiopharma S.r.l.
- IrelandRyzneuta 20 mg solution for injectionFisiopharma SrL
- NetherlandsRyzneuta 20 mg oplossing voor injectieFisiopharma S.r.L.
- United StatesRYZNEUTAAcrotech Biopharma Inc
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ryzneuta
- Liechtenstein · Ryzneuta
- Norway · Ryzneuta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d8bf0ab7-420f-475e-80b0-6e3a126e28eb GET /v1/drugs/d8bf0ab7-420f-475e-80b0-6e3a126e28eb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Ryzneuta 20 mg",
"name_fr": "Ryzneuta 20 mg",
"name_nl": "Ryzneuta 20 mg",
"amp_code": "SAM662602-00",
"strengths": [
"20.0000",
"20.0000",
"20.0000",
"50.0000",
"50.0000"
],
"pack_count": 1,
"substances": [
"Efbemalenograstim Alfa",
"Sodium Acetate Trihydrate",
"Sorbitol",
"Polysorbate 20"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Efbemalenograstim Alfa",
"authorisation_numbers": [
"EU/1/24/1793/001"
]
}See everything about efbemalenograstim alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.